Regulation of MicroRNA Expression and Abundance during Lymphopoiesis

Genomics and Immunity, NIAMS, NIH, Bethesda, MD 20892, USA.
Immunity (Impact Factor: 21.56). 06/2010; 32(6):828-39. DOI: 10.1016/j.immuni.2010.05.009
Source: PubMed


Although the cellular concentration of miRNAs is critical to their function, how miRNA expression and abundance are regulated during ontogeny is unclear. We applied miRNA-, mRNA-, and ChIP-Seq to characterize the microRNome during lymphopoiesis within the context of the transcriptome and epigenome. We show that lymphocyte-specific miRNAs are either tightly controlled by polycomb group-mediated H3K27me3 or maintained in a semi-activated epigenetic state prior to full expression. Because of miRNA biogenesis, the cellular concentration of mature miRNAs does not typically reflect transcriptional changes. However, we uncover a subset of miRNAs for which abundance is dictated by miRNA gene expression. We confirm that concentration of 5p and 3p miRNA strands depends largely on free energy properties of miRNA duplexes. Unexpectedly, we also find that miRNA strand accumulation can be developmentally regulated. Our data provide a comprehensive map of immunity's microRNome and reveal the underlying epigenetic and transcriptional forces that shape miRNA homeostasis.

Download full-text


Available from: Zhiyu Li,
  • Source
    • "Recent studies have revealed the critical role of miRNAs in tuning immunity. Immune cells express unique miRNA profiles which contribute to their respective functions (Kuchen et al., 2010) and change their miRNA repertoires in response to varying stimuli such as T cell receptor (TCR) activation (Bronevetsky et al., 2013). The past decade has seen many fascinating discoveries about the role of miRNAs in immunity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are 19-24 nucleotide long non-coding RNA species that regulate the expression of multiple target genes at the post-transcriptional level. They are required for normal immune system development and function, and their expression is dynamically regulated in different immune cell subsets during lineage differentiation and immune response. Aberrant expression of miRNAs results in dysregulated innate and adaptive immunity. This in turn can lead to failure to fight against invading pathogens and the development of autoimmune diseases and hematopoietic malignancies. In this article, we review current progress in miRNA research in immunity in both physiological and pathological settings. We also discuss research limitations and challenges that researchers are just beginning to solve.
    Frontiers in Genetics 06/2014; 5:178. DOI:10.3389/fgene.2014.00178
  • Source
    • "MiR- 27 is ubiquitously expressed in many tissues and cell types. However, T cells express the highest levels of miR-27 (Kuchen et al., 2010), suggesting that miR-27 functions in regulating T cell responses. T cell receptor/CD3 complex (TCR) signaling is important for proliferation, differentiation, and cell death during T cell development ; it also contributes to clonal expansion and effector cytokine secretion during T cell activation (Murphy et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In marmoset T cells transformed by Herpesvirus saimiri (HVS), a viral U-rich noncoding (nc) RNA, HSUR 1, specifically mediates degradation of host microRNA-27 (miR-27). High-throughput sequencing of RNA after crosslinking immunoprecipitation (HITS-CLIP) identified mRNAs targeted by miR-27 as enriched in the T cell receptor (TCR) signaling pathway, including GRB2. Accordingly, transfection of miR-27 into human T cells attenuates TCR-induced activation of mitogen-activated protein kinases (MAPKs) and induction of CD69. MiR-27 also robustly regulates SEMA7A and IFN-γ, key modulators and effectors of T cell function. Knockdown or ectopic expression of HSUR 1 alters levels of these proteins in virally transformed cells. Two other T-lymphotropic γ-herpesviruses, AlHV-1 and OvHV-2, do not produce a noncoding RNA to downregulate miR-27 but instead encode homologs of miR-27 target genes. Thus, oncogenic γ-herpesviruses have evolved diverse strategies to converge on common targets in host T cells.
    Molecular cell 04/2014; 54(1):67-79. DOI:10.1016/j.molcel.2014.03.025 · 14.02 Impact Factor
  • Source
    • "Also, differences in circulating miRNAs that are expressed at low levels may have been missed. Other techniques that are not limited in the number of miRNAs, such as small RNA sequencing using deep sequencing platforms, have been shown to be very useful to investigate this [39,40]. Besides the use of a different analytical platform, one might also consider using PAXgene blood instead of plasma. "
    [Show abstract] [Hide abstract]
    ABSTRACT: JC polyomavirus (JCPyV) is a widespread human polyomavirus that usually resides latently in its host. It can be reactivated under immunomodulating conditions and cause Progressive Multifocal Leukoencephalopathy (PML). Circulating microRNAs (miRNAs) are emerging as promising biomarkers for several pathologies. In this study, we have investigated whether circulating miRNAs exist that are differentially expressed between JCPyV seropositive and JCPyV seronegative on the one hand or between JCPyV shedders and JCPyV non-shedders on the other hand. Human miRNA expression profiling was performed in a small set of plasma samples obtained from seronegative subjects, seropositive shedders and seropositive non-shedders. A set of 10 miRNAs was selected for further analysis in a larger group of samples. Based on the plasma profiling experiment of 30 samples, 6 miRNAs were selected that were possibly differentially expressed between seropositive and seronegative subjects and 4 miRNAs were selected that were possibly differentially expressed between shedders and non-shedders. Subsequently, expression of these 10 selected miRNAs was assessed in an independent set of 100 plasma samples. Results indicated that none of them were differentially expressed. This study could not identify circulating human miRNAs that were differentially expressed between plasma from JCPyV seropositive and JCPyV seronegative subjects or between JCPyV shedders and JCPyV non-shedders.
    Virology Journal 03/2014; 11(1):41. DOI:10.1186/1743-422X-11-41 · 2.18 Impact Factor
Show more